Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Lechun Biotechnology

Request full access

Single-use bioprocessing solutions for the biopharmaceutical industry

Songjiang District, ChinaFounded 2011Biotech & Life Sciences

About Shanghai Lechun Biotechnology

Shanghai LePure Biotech Co., Ltd. is a provider of single-use bioprocessing solutions for the biopharmaceutical industry. Founded in 2011 by Chairwoman Qin Sunxing and co-founder and CEO Frank Wang, the company was one of the first domestic providers of single-use consumables and equipment for biopharmaceutical companies in China. LePure Biotech offers a comprehensive product suite that covers the entire biopharmaceutical process, from upstream cell cultivation to downstream separation and purification, and final drug formulation and filling.

The company's offerings include single-use bags, tubing and assemblies, bioreactors, filters, and fluid management equipment. Through strategic acquisitions, LePure has expanded its portfolio to include filtration and purification solutions, as well as cell culture media. In November 2022, the company acquired QuaCell Biotechnology, entering the cell culture media business. This was followed by the acquisition of GeShi Fluid in January 2023, which has over 20 years of experience in filtration and purification technology, significantly strengthening LePure's position in the filtration market.

LePure Biotech operates with a vertically integrated manufacturing model, controlling the process from in-house film extrusion to final product assembly to ensure quality and consistency. The company serves biopharmaceutical clients, including those in monoclonal antibody, vaccine, and cell therapy sectors, and has provided solutions to over 600 biopharmaceutical companies in China, while also exporting to the USA, Singapore, South Korea, and Germany. The firm has received significant investment from world-renowned investors. In January 2023, it closed a Series C financing round co-led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management. These funds are intended to accelerate product innovation and support overseas expansion.

Source: Dealroom company data

At a glance

Status
Operational
Employees
54
Open positions
None listed
Dealroom signal
43.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Jan 2023 $28M $110M General Atlantic · Goldman Sachs · HM Capital · Honghui Capital ↗
SERIES BOther financing Dec 2021 $0 — New Alliance Capital · Hillhouse Capital · Huimei Technology —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Lechun Biotechnology website traffic

Latest recorded traffic for Shanghai Lechun Biotechnology is 20 monthly website visits, down 89.5% over the last three months. Shanghai Lechun Biotechnology's team grew 5.9% over the past year.

Latest monthly visits20 3-month web change-89.5% 1-year team growth+5.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shanghai Lechun Biotechnology in the Songjiang District ecosystem

Live from Dealroom

The Shanghai Lechun Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later8 investors entered at this stage

  • General Atlantic
  • Goldman Sachs
  • HM Capital
  • Honghui Capital
  • Huaying Health Fund
  • Novo Holdings
  • China Science and Technology Innovation
  • Kangjun Capital
Employees 54 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Songjiang District HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Lechun Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Lechun Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.